Mind Medicine (MindMed) Inc. (MNMD) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
5.56
-7% vs avg
5yr avg: 5.99
30Y Low0.1·High20.3
ROE
↑
-64.1%
↓+4% vs avg
5yr avg: -67.0%
30Y Low-87%·High-23%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MNMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Mind Medicine (MindMed) Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $1.2B | $4.9B | $143M | $68M | $567M | $812M | $267485 | $468822 | $1M | — |
| Enterprise Value | $1.8B | $938M | $4.7B | $58M | $-74183581 | $433M | $732M | $249554 | $314031 | $1M | — |
| P/E Ratio → | -10.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 5.56 | 3.60 | 20.31 | 1.83 | 0.45 | 3.74 | 10.70 | 0.10 | 0.13 | 0.36 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MNMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MNMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -64.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.1% | -64.1% | -68.0% | -83.6% | -37.5% | -81.8% | -86.8% | -35.6% | -23.0% | -60.2% | -87.4% |
| ROA | -49.5% | -49.5% | -50.9% | -65.0% | -34.0% | -75.8% | -80.8% | -34.5% | -22.7% | -58.0% | -72.8% |
| ROIC | -389.5% | -389.5% | — | -10014.2% | -368.9% | -1012.9% | — | -11.5% | -17.6% | -45.5% | -42.2% |
| ROCE | -52.2% | -52.2% | -58.4% | -76.8% | -43.4% | -80.9% | -81.3% | -15.0% | -23.1% | -60.6% | -54.1% |
MNMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $258M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.09 | 0.18 | 0.00 | — | — | — | — | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.78 | -1.04 | -1.10 | -0.94 | -0.88 | -1.06 | -0.01 | -0.04 | 0.00 | -0.09 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -45.52 | -102.03 | -44.37 | -261.43 | -201.40 | — | — | — | — |
Net cash position: cash ($258M) exceeds total debt ($0)
MNMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Mind Medicine (MindMed) Inc.'s current ratio of 6.29x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.22x to 6.29x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.29 | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 | 27.10 | 14.76 | 24.14 | 22.03 | 1.80 |
| Quick Ratio | 6.29 | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 | 27.10 | 14.76 | 24.14 | 22.03 | 1.80 |
| Cash Ratio | 6.17 | 6.17 | 7.05 | 3.09 | 7.94 | 12.83 | 26.63 | 0.09 | 18.81 | 21.02 | 1.71 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | 7537.35 | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
MNMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Mind Medicine (MindMed) Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $89M | $705M | $39M | $31M | $27M | $18M | $379411 | $312548 | $252818 | $80416 |
Peer Comparison
Compare MNMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MNMDYou | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 CMPS | $896M | -3.0 | — | — | — | — | -565.3% | — | — |
 ATAI | $962M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 CYBN | $304M | -13.7 | — | — | — | — | -42.8% | -115.8% | — |
 MGRX | $5M | -0.1 | — | — | 61.7% | -1294.4% | -118.3% | -83.8% | — |
 SILO | $2M | -0.4 | — | — | 91.9% | -6526.4% | -78.4% | -186.7% | — |
 LWAY | $406M | 29.9 | 19.9 | — | 27.4% | 7.6% | 17.6% | 17.8% | 0.0 |
 ENVB | $145840 | -0.0 | — | — | — | — | -539.6% | — | — |
 JAZZ | $13B | -36.3 | 22.6 | 10.3 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 INVA | $2B | 6.9 | 5.6 | 8.6 | 72.3% | 38.5% | 29.1% | 16.8% | — |
 AXSM | $11B | -60.6 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
See MNMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MNMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MNMD vs CMPS
Side-by-side business, growth, and profitability comparison vs COMPASS Pathways plc.
Start ComparisonMNMD — Frequently Asked Questions
Quick answers to the most common questions about buying MNMD stock.
What is Mind Medicine (MindMed) Inc.'s P/E ratio?
Mind Medicine (MindMed) Inc.'s current P/E ratio is -10.0x. This places it at the 50th percentile of its historical range.
What is Mind Medicine (MindMed) Inc.'s ROE?
Mind Medicine (MindMed) Inc.'s return on equity (ROE) is -64.1%. The historical average is -60.1%.
Is MNMD stock overvalued?
Based on historical data, Mind Medicine (MindMed) Inc. is trading at a P/E of -10.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.